This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Oncology  • Cervical Cancer  • Immunization  • Quality of Care  • Patient Safety/ Medical Error  • Women's Health  • Women's Health, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Charlotte Haug, MD, PhD, MSc

JAMA. 2009;302(7):795-796.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

When do physicians know enough about the beneficial effects of a new medical intervention to start recommending or using it? When is the available information about harmful adverse effects sufficient to conclude that the risks outweigh the potential benefits? If in doubt, should physicians err on the side of caution or on the side of hope? These questions are at the core of all medical decision making. It is a complicated process because medical knowledge is typically incomplete and ambiguous. It is especially complex to make decisions about whether to use drugs that may prevent disease in the future, particularly when these drugs are given to otherwise healthy individuals. Vaccines are examples of such drugs, and the human papillomavirus (HPV) vaccine is a case in point.

zur Hausen, winner of the Nobel Prize in Physiology or Medicine in 2008, discovered that oncogenic HPV causes cervical . . . [Full Text of this Article]

Author Affiliation: The Journal of the Norwegian Medical Association, Oslo, Norway.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Barbara A. Slade, Laura Leidel, Claudia Vellozzi, Emily Jane Woo, Wei Hua, Andrea Sutherland, Hector S. Izurieta, Robert Ball, Nancy Miller, M. Miles Braun, Lauri E. Markowitz, and John Iskander
JAMA. 2009;302(7):750-757.
ABSTRACT | FULL TEXT  

Marketing HPV Vaccine: Implications for Adolescent Health and Medical Professionalism
Sheila M. Rothman and David J. Rothman
JAMA. 2009;302(7):781-786.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

HPV Vaccine: Postlicensure Safety Data
Rathore
AAP Grand Rounds 2009;22:51-51.
FULL TEXT  

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States
Kim and Goldie
BMJ 2009;339:b3884-b3884.
ABSTRACT | FULL TEXT  

Quadrivalent HPV Vaccine: Postlicensure Safety Data and Marketing Controversies
JWatch Women's Health 2009;2009:1-1.
FULL TEXT